Aaron H. Morris

Immunology and Microbiology · University of Michigan

Mid career · publishing since 2003Rising activity

Immunotherapy and Immune Responses Immune cells in cancer Tissue Engineering and Regenerative Medicine Cancer Immunotherapy and Biomarkers Tracheal and airway disorders

Publications

Citations

1,271

Est. group size

~10

Recurring co-author estimate

Active years

Publishing since 2003

In context

Among 267 mid career Immunology and Microbiology PIs within our index

Citations: 1,271cohort median 916

Publications / year (recent): 11.0cohort median 3.2

Typically publishes in teams of ~7 · 19% small-team papers (≤3 authors) · across 17 venues

Publication cadence

Publications per year over the last 10 years — averaging 11.0/year recently

Collaborators per year

Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.

Recent publications

Don’t judge an implant by its cover: how the foreign body response and fibrotic capsule might be harnessed for good
npj Biomedical Innovations. · 2026
Antigen-delivering biomaterials for local enrichment and reprogramming of immune cells
Journal of Controlled Release · 2026
Conversion of natural cytokine receptors into orthogonal synthetic biosensors
Nature Chemical Biology · 2025
Antigen-conjugated scaffolds enable sustained delivery of antigen and enrichment of antigen-specific T-cells
Journal of Controlled Release · 2025
Conversion of natural cytokine receptors into orthogonal synthetic biosensors
bioRxiv (Cold Spring Harbor Laboratory) · 2024
529 Comparison of the clinical biomarkers dMMR, MSI-H and PD-L1 with cytokines secreted from anti-PD-1 treated human live tumor fragments on an ex vivo platform
Regular and Young Investigator Award Abstracts · 2024
Data from Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
2023
Supplementary Data from Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
2023
Supplementary Data from Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
2023
Data from Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
2023
Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
Cancer Research · 2021
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
Regular and Young Investigator Award Abstracts · 2020
O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab
Oral Presentations · 2020
604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma
Regular and Young Investigator Award Abstracts · 2020
Elevated Thrombospondin 2 Contributes to Delayed Wound Healing in Diabetes
Diabetes · 2019

Publishes in

Cancer Research×8
Regular and Young Investigator Award Abstracts×3
bioRxiv (Cold Spring Harbor Laboratory)×3
Nature Communications×2
Proceedings of the National Academy of Sciences×2

Similar researchers

By research-topic overlap

Marisa Aikins
Immunology and Microbiology · University of Michigan
Houjun Xia
Immunology and Microbiology · University of Michigan
James J. Moon
Immunology and Microbiology · University of Michigan
Athanasios Papadas
Immunology and Microbiology · The Ohio State University
Diana M. Lopez
Immunology and Microbiology · The Ohio State University

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 25, 2026.

Claim or correct this profile